Guardant Health (GH) Q3 2026 Earnings Call Transcript

Guardant Health reported Q3 revenue of $361 million, up 36% year over year, and raised 2026 revenue guidance to $1.36 billion–$1.37 billion, implying 38%–40% growth. Screening revenue rose 180% to $68 million as Shield volume increased 246% to 83,000 tests; Shield cost per test fell to $330 from $410 in Q2, ahead of the company’s $350 year-end target. Management raised free-cash-flow-burn guidance to $205 million–$220 million, citing a $10 million–$15 million CMS payment delay into 2027, while reiterating its target for company-wide cash-flow breakeven by the end of 2027.

Analysis

The investable signal is not headline growth but whether Guardant can convert expanding test use into repeatable, reimbursed gross profit. Serial monitoring and Smart Apps could increase tests per oncology patient; if adoption shifts from one-time profiling to recurring treatment decisions, revenue durability and the platform multiple improve. That remains a hypothesis until repeat-testing rates, payer coverage, and realized reimbursement are visible. Shield’s lower test cost helps, but does not establish fully loaded profitability: field-force and marketing investment are still rising, while broader commercial coverage could initially dilute realized ASP before contracts mature.

Near term, the CMS code delay is a collection-timing issue as described by management, not evidence of lost demand; however, it makes reported cash conversion less clean into early 2027. Over 1–3 months, watch Shield volume, ASP/mix, and CMS payment processing. Over 6–18 months, key gates are commercial payer contracting, ADLT designation, Reveal reimbursement, and FDA review of Guardant360 Tissue. Management’s cash-flow milestones depend on these execution and reimbursement steps, not just test growth.

The contrarian risk is that investors extrapolate high Shield volume growth while underweighting acquisition costs, payer economics, and the clinical/regulatory work still required for multi-cancer screening and Reveal Ultra. AstraZeneca may benefit from treatment selection, but the call provides no basis to quantify a material financial contribution to AZN.

Key Decisions for Investors

• Avoid chasing GH at the open without checking the post-call price move and valuation. For accounts seeking exposure, consider a modest, staged long only if the market reaction does not price in flawless 2027 execution; no numeric target is justified by the supplied data. Thesis is falsified by a material cut to revenue guidance, weakening Shield volumes, or persistent deterioration in ASP/mix.
• Use Shield as the near-term operating dashboard: verify sequential volume growth alongside realized ASP, payer contract terms, and the trend in test cost. Treat coverage announcements as access—not proof of paid claims or attractive economics—until collections establish that conversion.
• Track the CMS code update and recovery of the delayed Guardant360 Liquid CDx payments in early 2027. A further delay or evidence of denied/uncollectible claims would turn a stated timing headwind into a cash-conversion concern; it would also weaken confidence in the company-wide breakeven timeline.
• Keep Reveal Ultra, Guardant360 Tissue PMA/ADLT, and Shield multi-cancer detection on a catalyst watchlist rather than underwriting them as current earnings drivers. Reassess when clinical data, FDA decisions, and reimbursement evidence are independently available.